Progression from Steroid Responsive to Unresponsive State in Breast Cancer --;Drug Resistance --;Integration of Quality-of-Life Issues into Clinical Trials of Breast Cancer --;Adjuvant Systemic Therapy for Breast Cancer Patients Without Lymph Node Metastases (N- ) --;New Developments in the Field of Aromatase Inhibitors --;Resistance to Antioestrogen Therapy: a Challenge for the Future --;New Antioestrogens Without Oestrogenic Activity.
SUMMARY OR ABSTRACT
Text of Note
This volume is the third in a series of yearly reports from the European School of Oncology (Task Force) on endocrine aspects of breast cancer. The contributions stem from outstanding researchers in the field and give provocative discussions of current, controversial topics. This year's three main topics were 1) natural and acquired resistance, 2) adjuvant treatment and quality of life, and 3) new endocrine agents. This state-of-the-art update invites the reader to critically review developments in basic research and methodological problems related to clinical trials.